Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011 (2011), Article ID 856190, 15 pages
http://dx.doi.org/10.1155/2011/856190
Review Article

Pathobiologic Markers of the Ewing Sarcoma Family of Tumors: State of the Art and Prediction of Behaviour

1Calgary Laboratory Services, University of Calgary, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, AB, Canada T3B 6A8
2Department of Pathology, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ 85016, USA
3Departments of Pathology and Pediatrics, University of Arizona, College of Medicine, Phoenix, AZ 85016, USA
4Health Sciences Center, University of Oklahoma, Oklahoma City, OK 73104, USA

Received 6 July 2010; Revised 20 September 2010; Accepted 23 September 2010

Academic Editor: R. Pollock

Copyright © 2011 Alfredo Pinto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ewing, “Diffuse endothelioma of bone,” Proceedings of the New York Pathology Society, vol. 21, pp. 17–24, 1921. View at Google Scholar
  2. R. Moll, V. E. Gould, and R. Berndt, “Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiation,” American Journal of Pathology, vol. 127, no. 2, pp. 288–304, 1987. View at Google Scholar · View at Scopus
  3. A. O. Cavazzana, J. S. Miser, J. Jefferson, and T. J. Triche, “Experimental evidence for a neural origin of Ewing's sarcoma of bone,” American Journal of Pathology, vol. 127, no. 3, pp. 507–518, 1987. View at Google Scholar · View at Scopus
  4. M. Lipinski, K. Braham, and I. Philip, “Neuroectoderm-associated antigens on Ewing's sarcoma cell lines,” Cancer Research, vol. 47, no. 1, pp. 183–187, 1987. View at Google Scholar · View at Scopus
  5. M. Lipinski, M.-R. Hirsch, and H. Deagostini-Bazin, “Characterization of neural cell adhesion molecules (NCAM) expressed by ewing and neuroblastoma cell lines,” International Journal of Cancer, vol. 40, no. 1, pp. 81–86, 1987. View at Google Scholar · View at Scopus
  6. K. Kawaguchi and M. Koike, “Neuron-specific enolase and Leu-7 immunoreactive small round-cell neoplasm: the relationship to Ewing's sarcoma in bone and soft tissue,” American Journal of Clinical Pathology, vol. 86, no. 1, pp. 79–83, 1986. View at Google Scholar · View at Scopus
  7. A. Llombart-Bosch, M. J. Lacombe, G. Contesso, and A. Peydro-Olaya, “Small round blue cell sarcoma of bone mimicking atypical Ewing's sarcoma with neuroectodermal features. An analysis of five cases with immunohistochemical and electron microscopic support,” Cancer, vol. 60, no. 7, pp. 1570–1582, 1987. View at Google Scholar · View at Scopus
  8. A. P. Stout, “A tumor of the ulnar nerve,” Proceedings of the New York Pathology Society, vol. 18, pp. 2–12, 1918. View at Google Scholar
  9. L. Angervall and F. M. Enzinger, “Extraskeletal neoplasm resembling Ewing's sarcoma,” Cancer, vol. 36, no. 1, pp. 240–251, 1975. View at Google Scholar · View at Scopus
  10. E. H. Soule, W. Newton Jr., T. E. Moon, and M. Tefft, “Extraskeletal Ewing's sarcoma. A preliminary review of 26 cases encountered in the intergroup rhabdomyosarcoma study,” Cancer, vol. 42, no. 1, pp. 259–264, 1978. View at Google Scholar · View at Scopus
  11. A. G. Nascimento, K. L. Cooper, and K. K. Unni, “A clinicopathologic study of 20 cases of large-cell (atypical) Ewing's sarcoma of bone,” American Journal of Surgical Pathology, vol. 4, no. 1, pp. 29–36, 1980. View at Google Scholar · View at Scopus
  12. F. B. Askin, J. Rosal, and R. K. Sibley, “Malignant small cell tumor of the thoracopulmonary region in childhood. A distinctive clinicopathologic entity of uncertain histogenesis,” Cancer, vol. 43, no. 6, pp. 2438–2451, 1979. View at Google Scholar · View at Scopus
  13. R. Jaffe, M. Santamaria, and E. J. Yunis, “The neuroectodermal tumor of bone,” American Journal of Surgical Pathology, vol. 8, no. 12, pp. 885–898, 1984. View at Google Scholar · View at Scopus
  14. D. Schmidt, B. Mackay, and A. G. Ayala, “Ewing's sarcoma with neuroblastoma-like features,” Ultrastructural Pathology, vol. 3, no. 2, pp. 143–151, 1982. View at Google Scholar · View at Scopus
  15. L. P. Dehner, “Peripheral and central primitive neuroectodermal tumors. A nosologic concept seeking a consensus,” Archives of Pathology and Laboratory Medicine, vol. 110, no. 11, pp. 997–1005, 1986. View at Google Scholar · View at Scopus
  16. L. P. Dehner, “Primitive neuroectodermal tumor and Ewing's sarcoma,” American Journal of Surgical Pathology, vol. 17, no. 1, pp. 1–13, 1993. View at Publisher · View at Google Scholar · View at Scopus
  17. E. J. Yunis, “Ewing's sarcoma and related small round cell neoplasms in children,” American Journal of Surgical Pathology, vol. 10, pp. 54–62, 1986. View at Google Scholar · View at Scopus
  18. S. Navarro, A. O. Cavazzana, A. Llombart-Bosch, and T. J. Triche, “Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma: an immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms,” Archives of Pathology and Laboratory Medicine, vol. 118, no. 6, pp. 608–615, 1994. View at Google Scholar · View at Scopus
  19. M. C. Le Deley, O. Delattre, K. L. Schaefer et al., “Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 1982–1988, 2010. View at Publisher · View at Google Scholar
  20. N. Riggi, L. Cironi, P. Provero et al., “Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells,” Cancer Research, vol. 65, no. 24, pp. 11459–11468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Tirode, K. Laud-Duval, A. Prieur, B. Delorme, P. Charbord, and O. Delattre, “Mesenchymal stem cell features of ewing tumors,” Cancer Cell, vol. 11, no. 5, pp. 421–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Ordóñez, D. Osuna, D. Herrero, E. De Álava, and J. Madoz-Gúrpide, “Advances in Ewing's sarcoma research: where are we now and what lies ahead?” Cancer Research, vol. 69, no. 18, pp. 7140–7150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. A. L. Folpe, J. R. Goldblum, B. P. Rubin et al., “Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases,” American Journal of Surgical Pathology, vol. 29, no. 8, pp. 1025–1033, 2005. View at Google Scholar · View at Scopus
  24. A. Llombart-Bosch, I. Machado, S. Navarro et al., “Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support,” Virchows Archiv, vol. 455, no. 5, pp. 397–411, 2009. View at Publisher · View at Google Scholar
  25. P. S. Dickman, “Electron microscopy for diagnosis of tumors in children,” Perspectives in pediatric pathology, vol. 9, pp. 171–213, 1987. View at Google Scholar · View at Scopus
  26. J. M. Kissane, F. B. Askin, and M. Foulkes, “Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study,” Human Pathology, vol. 14, no. 9, pp. 773–779, 1983. View at Google Scholar · View at Scopus
  27. D. Schmidt, C. Herrmann, H. Jurgens, and D. Harms, “Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma: a report from the Kiel Pediatric Tumor Registry,” Cancer, vol. 68, no. 10, pp. 2251–2259, 1991. View at Google Scholar · View at Scopus
  28. A. Pinto, L. H. Grant, F. A. Hayes, M. J. Schell, and D. M. Parham, “Immunohistochemical expression of neuron-specific enolase and Leu 7 in Ewing's sarcoma of bone,” Cancer, vol. 64, no. 6, pp. 1266–1273, 1989. View at Google Scholar · View at Scopus
  29. M. Ladanyi, F. S. Heinemann, A. G. Huvos, P. H. Rao, Q. Chen, and S. C. Jhanwar, “Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t(11;22)(q24;q12): an immunohistochemical study of 11 cases,” Human Pathology, vol. 21, no. 12, pp. 1245–1251, 1990. View at Google Scholar · View at Scopus
  30. J. A. Bridge, M. E. Fidler, J. R. Neff et al., “Adamantinoma-like Ewing's sarcoma: genomic confirmation, phenotypic drift,” American Journal of Surgical Pathology, vol. 23, no. 2, pp. 159–165, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Kanamori, C. R. Antonescu, M. Scott et al., “Extra copies of chromosomes 7, 8, 12, 19, and 21 are recurrent in Adamantinoma,” Journal of Molecular Diagnostics, vol. 3, no. 1, pp. 16–21, 2001. View at Google Scholar · View at Scopus
  32. F. M. Enzinger and S. W. Weiss, Soft Tissue Tumors, Mosby, St. Louis, Mo, USA, 1st edition, 1983.
  33. A. O. Cavazzana, V. Ninfo, J. Roberts, and T. J. Triche, “Peripheral neuroepithelioma: a light microscopic, immunocytochemical, and ultrastructural study,” Modern Pathology, vol. 5, no. 1, pp. 71–78, 1992. View at Google Scholar · View at Scopus
  34. R. L. Katz, M. Quezado, A. M. Senderowicz, L. Villalba, W. B. Laskin, and M. Tsokos, “An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript,” Human Pathology, vol. 28, no. 4, pp. 502–509, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. T. J. Triche, F. B. Askin, and J. Kissane, “Neuroblastoma, Ewing's sarcoma, and the differential diagnosis of small-, round-, blue-cell tumors,” in Major Problems in Pathology: Pathology of Neoplasia in Children and Adolescents, M. Finegold, Ed., pp. 145–195, WB Saunders, Philadelphia, Pa, USA, 1986. View at Google Scholar
  36. S. Williams, D. M. Parham, and J. J. Jenkins III, “Peripheral neuroepithelioma with ganglion cells: report of two cases and review of the literature,” Pediatric and Developmental Pathology, vol. 2, no. 1, pp. 42–49, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. S. R. Knezevich, G. Hendson, J. A. Mathers et al., “Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma,” Human Pathology, vol. 29, no. 3, pp. 289–294, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. A. J. Stevenson, J. Chatten, F. Bertoni et al., “CD99 (p30/32MIC2) neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumors and the literature experience,” Applied Immunohistochemistry, vol. 2, no. 2, pp. 231–240, 1994. View at Google Scholar
  39. A. L. Folpe, C. E. Hill, D. M. Parham, P. A. O'Shea, and S. W. Weiss, “Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor,” American Journal of Surgical Pathology, vol. 24, no. 12, pp. 1657–1662, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. D. M. Parham, “Ewing's sarcoma, peripheral neuroepithelioma, and related tumors,” in Pediatric Neoplasia: Morphology and Biology, D. M. Parham, Ed., pp. 65–85, Raven Press, New York, NY, USA, 1996. View at Google Scholar
  41. H. Kovar, M. Dworzak, S. Strehl et al., “Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor,” Oncogene, vol. 5, no. 7, pp. 1067–1070, 1990. View at Google Scholar · View at Scopus
  42. V. Cerisano, Y. Aalto, S. Perdichizzi et al., “Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators,” Oncogene, vol. 23, no. 33, pp. 5664–5674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Schenkel, E. M. Dufour, T. W. Chew, E. Sorg, and W. A. Muller, “The murine CD99-related molecule CD99-like 2 (CD99L2) is an adhesion molecule involved in the inflammatory response,” Cell Communication and Adhesion, vol. 14, no. 5, pp. 227–237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Rocchi, M. C. Manara, M. Sciandra et al., “CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis,” The Journal of Clinical Investigation, vol. 120, no. 3, pp. 668–680, 2010. View at Publisher · View at Google Scholar
  45. O. Delattre, J. Zucman, B. Plougastel et al., “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature, vol. 359, no. 6391, pp. 162–165, 1992. View at Publisher · View at Google Scholar · View at Scopus
  46. A. D. Sharrocks, A. L. Brown, Y. Ling, and P. R. Yates, “The ETS-domain transcription factor family,” International Journal of Biochemistry and Cell Biology, vol. 29, no. 12, pp. 1371–1387, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Nilsson, M. Wang, J. Wejde, A. Kreicbergs, and O. Larsson, “Detection of EWS/FLI-1 by immunostaining. An adjunctive tool in diagnosis of Ewing's sarcoma and primitive neuroectodermal tumour on cytological samples and paraffin-embedded archival material,” Sarcoma, vol. 3, no. 1, pp. 25–32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Llombart-Bosch and S. Navarro, “Immunohistochemical detection of EWS and FLI-1 proteins in ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression,” Applied Immunohistochemistry and Molecular Morphology, vol. 9, no. 3, pp. 255–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. E. J. Smart, G. A. Graf, M. A. McNiven et al., “Caveolins, liquid-ordered domains, and signal transduction,” Molecular and Cellular Biology, vol. 19, no. 11, pp. 7289–7304, 1999. View at Google Scholar · View at Scopus
  50. T. M. Williams and M. P. Lisanti, “Caveolin-1 in oncogenic transformation, cancer, and metastasis,” American Journal of Physiology, vol. 288, no. 3 57-3, pp. C494–C506, 2005. View at Publisher · View at Google Scholar
  51. O. M. Tirado, S. Mateo-Lozano, J. Villar et al., “Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells,” Cancer Research, vol. 66, no. 20, pp. 9937–9947, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. P. S. Dickman and T. J. Triche, “Extraosseous Ewing's sarcoma versus primitive rhabdomyosarcoma: diagnostic criteria and clinical correlation,” Human Pathology, vol. 17, no. 9, pp. 881–893, 1986. View at Google Scholar · View at Scopus
  53. H. Shimada, W. A. Newton Jr., E. H. Soule, S. J. Qualman, C. Aoyama, and H. M. Maurer, “Pathologic features of extraosseous Ewing's sarcoma: a report from the intergroup rhabdomyosarcoma study,” Human Pathology, vol. 19, no. 4, pp. 442–453, 1988. View at Google Scholar · View at Scopus
  54. D. M. Parham, Y. Hijazi, S. M. Steinberg et al., “Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior,” Human Pathology, vol. 30, no. 8, pp. 911–918, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. D. M. Parham, P. Dias, D. R. Kelly, J. C. Rutledge, and P. Houghton, “Desmin positivity in primitive neuroectodermal tumors of childhood,” American Journal of Surgical Pathology, vol. 16, no. 5, pp. 483–492, 1992. View at Google Scholar · View at Scopus
  56. P. Thorner, J. Squire, S. Chilton-MacNeill et al., “Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types,” American Journal of Pathology, vol. 148, no. 4, pp. 1125–1138, 1996. View at Google Scholar · View at Scopus
  57. P. H. B. Sorensen, H. Shimada, X. F. Liu, J. F. Lim, G. Thomas, and T. J. Triche, “Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene,” Cancer Research, vol. 55, no. 6, pp. 1385–1392, 1995. View at Google Scholar · View at Scopus
  58. D. R. Boué, D. M. Parham, B. Webber, W. M. Crist, and S. J. Qualman, “Clinicopathologic study of ectomesenchymomas from intergroup rhabdomyosarcoma study groups III and IV,” Pediatric and Developmental Pathology, vol. 3, no. 3, pp. 290–300, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. B. J. P. Huntly and D. G. Gilliland, “Cancer biology: summing up cancer stem cells,” Nature, vol. 435, no. 7046, pp. 1169–1170, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. M.-L. Suvà, N. Riggi, J.-C. Stehle et al., “Identification of cancer stem cells in Ewing's sarcoma,” Cancer Research, vol. 69, no. 5, pp. 1776–1781, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Jiang, Y. Gwye, D. Russell et al., “CD133 expression in chemo-resistant Ewing sarcoma cells,” BMC Cancer, vol. 10, article 116, 2010. View at Publisher · View at Google Scholar
  62. “Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-1981,” The New England Journal of Medicine, vol. 305, no. 14, pp. 814–823, 1981. View at Scopus
  63. S. L. Spunt, S. X. Skapek, and C. M. Coffin, “Pediatric nonrhabdomyosarcoma soft tissue sarcomas,” Oncologist, vol. 13, no. 6, pp. 668–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. E. De Alava and W. L. Gerald, “Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 204–213, 2000. View at Google Scholar · View at Scopus
  65. J. P. Ginsberg, E. De Alava, M. Ladanyi et al., “EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1809–1814, 1999. View at Google Scholar · View at Scopus
  66. F. Mertens, C. R. Antonescu, P. Hohenberger et al., “Translocation-related sarcomas,” Seminars in Oncology, vol. 36, no. 4, pp. 312–323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Romeo and A. P. Dei Tos, “Soft tissue tumors associated with EWSR1 translocation,” Virchows Archiv, vol. 456, no. 2, pp. 219–234, 2009. View at Google Scholar
  68. J. L. Ordóñez, D. Osuna, D. J. García-Domínguez et al., “The clinical relevance of molecular genetics in soft tissue sarcomas,” Advances in Anatomic Pathology, vol. 17, no. 3, pp. 162–181, 2010. View at Publisher · View at Google Scholar
  69. J. Zucman, T. Melot, C. Desmaze et al., “Combinatorial generation of variable fusion proteins in the Ewing family of tumours,” The EMBO Journal, vol. 12, no. 12, pp. 4481–4487, 1993. View at Google Scholar · View at Scopus
  70. F. G. Barr and R. B. Womer, “Molecular diagnosis of Ewing family tumors too many fusions...?” Journal of Molecular Diagnostics, vol. 9, no. 4, pp. 437–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. E. De Alava, A. Kawai, J. H. Healey et al., “EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1248–1255, 1998. View at Google Scholar · View at Scopus
  72. A. Zoubek, B. Dockhorn-Dworniczak, O. Delattre et al., “Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?” Journal of Clinical Oncology, vol. 14, no. 4, pp. 1245–1251, 1996. View at Google Scholar · View at Scopus
  73. E. De Alava, A. Kawai, J. H. Healey et al., “EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1248–1255, 1998. View at Google Scholar · View at Scopus
  74. R. Codrington, R. Pannell, A. Forster et al., “The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells,” PLoS Biology, vol. 3, no. 8, article e242, 2005. View at Publisher · View at Google Scholar
  75. L. Wang, R. Bhargava, T. Zheng et al., “Undifferentiated small roud cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions,” Journal of Molecular Diagnostics, vol. 9, no. 4, pp. 498–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Ordi, E. De Alava, A. Torné et al., “Intraabdominal desmoplastic small round cell tumor with EWS/ERG fusion transcript,” American Journal of Surgical Pathology, vol. 22, no. 8, pp. 1026–1032, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. D. C. Shing, D. J. McMullan, P. Roberts et al., “FUS/ERG gene fusions in Ewing's tumors,” Cancer Research, vol. 63, no. 15, pp. 4568–4576, 2003. View at Google Scholar · View at Scopus
  78. T. L. Ng, M. J. O'Sullivan, C. J. Pallen et al., “Ewing sarcoma with novel translocation t(2;16) producing an in-flame fusion of FUS and FEV,” Journal of Molecular Diagnostics, vol. 9, no. 4, pp. 459–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. G. Armengol, M. Tarkkanen, M. Virolainen et al., “Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization,” British Journal of Cancer, vol. 75, no. 10, pp. 1403–1409, 1997. View at Google Scholar · View at Scopus
  80. M. Tarkkanen, S. Kiuru-Kuhlefelt, C. Blomqvist et al., “Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors,” Cancer Genetics and Cytogenetics, vol. 114, no. 1, pp. 35–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. M. R. Nucci, S. Weremowicz, D. M. Neskey et al., “Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors,” Genes Chromosomes and Cancer, vol. 32, no. 2, pp. 164–171, 2001. View at Publisher · View at Google Scholar
  82. S. Savola, A. Klami, A. Tripathi et al., “Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors,” BMC Cancer, vol. 9, article 17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Ohali, S. Avigad, R. Zaizov et al., “Prediction of high risk Ewing's sarcoma by gene expression profiling,” Oncogene, vol. 23, no. 55, pp. 8997–9006, 2004. View at Publisher · View at Google Scholar
  84. K.-L. Schaefer, M. Eisenacher, Y. Braun et al., “Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy,” European Journal of Cancer, vol. 44, no. 5, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Smith, L. A. Owen, D. J. Trem et al., “Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma,” Cancer Cell, vol. 9, no. 5, pp. 405–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. L. A. Owen and S. L. Lessnick, “Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma,” Cell Cycle, vol. 5, no. 18, pp. 2049–2053, 2006. View at Google Scholar · View at Scopus
  87. J. D. Hancock and S. L. Lessnick, “A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature,” Cell Cycle, vol. 7, no. 2, pp. 250–256, 2008. View at Google Scholar · View at Scopus
  88. S. L. Lessnick, A. P. Dei Tos, P. H. B. Sorensen et al., “Small Round Cell Sarcomas,” Seminars in Oncology, vol. 36, no. 4, pp. 338–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Abudu, D. C. Mangham, G. M. Reynolds et al., “Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis,” British Journal of Cancer, vol. 79, no. 7-8, pp. 1185–1189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  90. E. De Alava, C. R. Antonescu, A. Panizo et al., “Prognostic impact of P53 status in Ewing sarcoma,” Cancer, vol. 89, no. 4, pp. 783–792, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. H.-Y. Huang, P. B. Illei, Z. Zhao et al., “Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 548–558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. S. C. Brownhill, C. Taylor, and S. A. Burchill, “Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT,” British Journal of Cancer, vol. 96, no. 12, pp. 1914–1923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. J.A. Lopez-Guerrero, I. Machado, K. Scotlandi et al., “Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors,” International Journal of Cancer. In press.
  94. I. Alldinger, K. L. Schaefer, D. Goedde et al., “Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression,” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 10, pp. 749–759, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Gangwal, S. Sankar, P. C. Hollenhorst et al., “Microsatellites as EWS/FLI response elements in Ewing's sarcoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 29, pp. 10149–10154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Gangwal and S. L. Lessnicke, “Microsatellites are EWS/FLI response elements: genomic “junk“ is EWS/FLI's treasure,” Cell Cycle, vol. 7, no. 20, pp. 3127–3132, 2008. View at Google Scholar · View at Scopus
  97. M. Kinsey, R. Smith, and S. L. Lessnick, “NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma,” Molecular Cancer Research, vol. 4, no. 11, pp. 851–859, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Riggi, M.-L. Suvà, D. Suvà et al., “EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells,” Cancer Research, vol. 68, no. 7, pp. 2176–2185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. E. C. Torchia, S. Jaishankar, and S. J. Baker, “Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells,” Cancer Research, vol. 63, no. 13, pp. 3464–3468, 2003. View at Google Scholar · View at Scopus
  100. N. Riggi, M.-L. Suvà, C. De Vito et al., “EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells,” Genes and Development, vol. 24, no. 9, pp. 916–932, 2010. View at Publisher · View at Google Scholar
  101. S. Hu-Lieskovan, J. Zhang, L. Wu et al., “EWS-FLI1 fusin protein up-regulates critical genes in neurtal crest development and is responsible for the observed phenotype of Ewing's family of tumors,” Cancer Research, vol. 65, no. 11, pp. 4633–4644, 2005. View at Google Scholar
  102. F. Baliko, T. Bright, R. Poon, B. Cohen, S. E. Egan, and B. A. Alman, “Inhibition of notch signaling induces neural differentiation in Ewing sarcoma,” American Journal of Pathology, vol. 170, no. 5, pp. 1686–1694, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. R. L. Shanfeld, J. Edelman, J. E. Willis, L. Tuason, and J. R. Goldblum, “Immunohistochemical analysis of neural markers in peripheral primitive neuroectodermal tumors (pPNET) without light microscopic evidence of neural differentiation,” Applied Immunohistochemistry and Molecular Morphology, vol. 5, no. 2, pp. 78–86, 1997. View at Google Scholar · View at Scopus
  104. D. M. Gascoyne, J. Dunne, S. Behjati, N. J. Sebire, J. Anderson, and D. S. Latchman, “EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A,” Oncogene, vol. 29, no. 21, pp. 3134–3145, 2010. View at Publisher · View at Google Scholar
  105. J. A. van Doorninck, L. Ji, B. Schaub et al., “Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the children's Oncology Group,” Journal of Clinical Oncology, vol. 28, no. 12, pp. 1989–1994, 2010. View at Publisher · View at Google Scholar
  106. H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,” The New England Journal of Medicine, vol. 348, no. 8, pp. 694–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. A. W. Craft, S. J. Cotterill, J. A. Bullimore, and D. Pearson, “Long-term results from the first UKCCSG Ewing's tumour study (ET-1),” European Journal of Cancer Part A, vol. 33, no. 7, pp. 1061–1069, 1997. View at Publisher · View at Google Scholar
  108. S. J. Cotterill, S. Ahrens, M. Paulussen et al., “Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3108–3114, 2000. View at Google Scholar
  109. N. Tageja, “Prognostic indicators for ewing's sarcoma,” The Lancet, vol. 376, no. 9737, p. 232, 2010. View at Google Scholar
  110. P. J. Leavey, L. Mascarenhas, N. Marina et al., “Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the children's oncology group,” Pediatric Blood and Cancer, vol. 51, no. 3, pp. 334–338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. R. Ladenstein, U. Pötschger, M. C. Le Deley et al., “Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3284–3291, 2010. View at Publisher · View at Google Scholar
  112. M. Paulussen, S. Ahrens, S. Burdach et al., “Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies,” Annals of Oncology, vol. 9, no. 3, pp. 275–281, 1998. View at Publisher · View at Google Scholar
  113. M. Paulussen, S. Ahrens, A. W. Craft et al., “Ewing tumors with primary lungmetastases: survival analysis of 114 (European Intergroup) Ewing Sarcoma Studies patients,” Journal of Clinical Oncology, vol. 16, pp. 3044–3052, 1998. View at Google Scholar
  114. C. Rodríguez-Galindo, T. Liu, M. J. Krasin et al., “Analysis of prognostic factors in Ewing sarcoma family of tumors,” Cancer, vol. 110, no. 2, pp. 375–384, 2007. View at Publisher · View at Google Scholar
  115. H. Jurgens, U. Exner, H. Gardner et al., “Multidisciplinary treatment of primary Ewing’s sarcoma of bone,” Cancer, vol. 7, pp. 208–213, 1988. View at Google Scholar
  116. J. S. Miser, M. D. Kraito, and N. J. Tarbell, “Treatment of metastatic Ewing’s sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide: a children’s Cancer group and Pediatric Oncology Group study,” Journal of Clinical Oncology, vol. 22, pp. 2873–2876, 2004. View at Google Scholar
  117. C. Rodríguez-Galindo, F. Navid, T. Liu, C. A. Billups, B. N. Rao, and M. J. Krasin, “Prognostic factors for local and distant control in Ewing sarcoma family of tumors,” Annals of Oncology, vol. 19, no. 4, pp. 814–820, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Rodriguez-Galindo, S. L. Spunt, and A. S. Pappo, “Review treatment of ewing sarcoma family of tumors: current status and outlook for the future,” Medical Pediatric Oncology, vol. 40, pp. 276–287, 2003. View at Google Scholar
  119. M. Paulussen, S. Ahrens, J. Dunst et al., “Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma study CESS 86,” Journal of Clinical Oncology, vol. 19, no. 6, pp. 1818–1829, 2001. View at Google Scholar · View at Scopus
  120. R. Derek Jenkin, I. Al-Fawaz, M. Al-Shabanah et al., “Localised Ewing sarcoma/PNET of bone—prognostic factors and international data comparison,” Medical and Pediatric Oncology, vol. 39, no. 6, pp. 586–593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. G. Bacci, S. Ferrari, A. Longhi et al., “Prognostic significance of serum LDH in Ewing's sarcoma of bone,” Oncology Reports, vol. 6, no. 4, pp. 807–811, 1999. View at Google Scholar · View at Scopus
  122. C. M. Hattinger, U. Potsguer, M. Tarkannen et al., “Prognostic impact of chromosomal aberrations in Ewing tumors,” British Journal of Cancer, vol. 86, pp. 1763–1769, 2002. View at Google Scholar
  123. G. Wei, C. R. Antonescu, E. De Alava et al., “Prognostic impact of INK4A deletion in Ewing sarcoma,” Cancer, vol. 89, no. 4, pp. 793–799, 2000. View at Publisher · View at Google Scholar · View at Scopus
  124. A. A. Gupta, A. Pappo, and N. Saunders, “Clinical outcome of children and adults with localized Ewing sarcoma, impact of chemotherapy dose and timing of local therapy,” Cancer, vol. 116, pp. 3189–3194, 2010. View at Google Scholar
  125. S. Ferrari, F. Bertoni, E. Palmerini et al., “Predictive factors of histologic response to primary chemotherapy in patients with ewing sarcoma,” Journal of Pediatric Hematology/Oncology, vol. 29, no. 6, pp. 364–368, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. G. Bacci, S. Ferrari, F. Bertoni et al., “Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 4–11, 2000. View at Google Scholar · View at Scopus
  127. M. W. Verrill, I. R. Judson, C. L. Harmer, C. Fisher, J. M. Thomas, and E. Wiltshaw, “Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children?” Journal of Clinical Oncology, vol. 15, no. 7, pp. 2611–2621, 1997. View at Google Scholar · View at Scopus
  128. K. Fizazi, N. Dohollou, J.-Y. Blay et al., “Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients,” Journal of Clinical Oncology, vol. 16, no. 12, pp. 3736–3743, 1998. View at Google Scholar · View at Scopus
  129. J. Lee, B. H. Hoang, A. Ziogas, and J. A. Zell, “Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry,” Cancer, vol. 116, no. 8, pp. 1964–1973, 2010. View at Publisher · View at Google Scholar
  130. F. A. Hayes, E. I. Thompson, W. H. Meyer et al., “Therapy for localized Ewing's sarcoma of bone,” Journal of Clinical Oncology, vol. 7, no. 2, pp. 208–213, 1989. View at Google Scholar · View at Scopus
  131. N. M. Marina, A. S. Pappo, D. M. Parham et al., “Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude children's research hospital,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 180–190, 1999. View at Google Scholar
  132. M. Paulussen, A. W. Craft, I. Lewis et al., “Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients,” Journal of Clinical Oncology, vol. 26, no. 27, pp. 4385–4393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. S. G. DuBois and H. E. Grier, “Chemotherapy: the role of ifosfamide and etoposide in Ewing sarcoma,” Nature Reviews Clinical Oncology, vol. 6, no. 5, pp. 251–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. R. Evans, M. Nesbit, and F. Askin, “Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non-metastatic Ewing's sarcoma of the pelvic bones,” International Journal of Radiation Oncology Biology Physics, vol. 11, no. 1, pp. 129–136, 1985. View at Google Scholar
  135. E. O. Burgert Jr., M. E. Nesbit, L. A. Garnsey et al., “Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II,” Journal of Clinical Oncology, vol. 8, no. 9, pp. 1514–1524, 1990. View at Google Scholar · View at Scopus
  136. A. Craft, S. Cotterill, A. Malcolm et al., “Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3628–3633, 1998. View at Google Scholar
  137. H. Grier, M. Krailo, and M. Link, “Improved outcome in non metastatic Ewing’s Sarcoma (ES) and PPNET of bone with the addition of ifosfamide (I) and etoposide (E) to vincristine (V), adryamicin (Ad), cyclophosphamide (C), and actinomycin (A) : A Children’s Cancer group (CCG) and Pediatrin Oncology Group (POG) report,” Procceedings Annual Meeting American Society Clinical Oncology, vol. 13, 1994, abstract no. 421. View at Google Scholar
  138. R. Luksch, G. Sampietro, P. Collini et al., “Prognostic value of clinicopathologic characteristics including neuroectodermal differentiation in osseous Ewing's sarcoma family of tumors in children,” Tumori, vol. 85, no. 2, pp. 101–107, 1999. View at Google Scholar
  139. L. Granowetter, R. Womer, M. Devidas et al., “Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: a children's oncology group study,” Journal of Clinical Oncology, vol. 27, no. 15, pp. 2536–2541, 2009. View at Publisher · View at Google Scholar
  140. P. S. Dickman, F. B. Askin, J. Miser et al., “Pathology and prognosis in osseous Ewing's sarcoma-primitive neuroectodermal tumor (ES/PNET): preliminary data analysis from CCG 7881/POG 8850,” Modern Pathology, vol. 12, p. 2, 1999. View at Google Scholar
  141. G. Bacci, C. Forni, A. Longhi et al., “Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992,” European Journal of Cancer, vol. 40, no. 1, pp. 73–83, 2004. View at Publisher · View at Google Scholar
  142. G. Bacci, A. Longhi, S. Ferrari, M. Mercuri, M. Versari, and F. Bertoni, “Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998,” Acta Oncologica, vol. 45, no. 4, pp. 469–475, 2006. View at Publisher · View at Google Scholar
  143. P. Marec-Bérard, F. Chotel, and L. Claude, “Tumeurs PNET/Ewing: prise en charge actuelle et perspectives,” Bulletin du Cancer, vol. 97, no. 6, pp. 707–713, 2010. View at Publisher · View at Google Scholar
  144. N. J. Balamuth and R. B. Womer, “Ewing's sarcoma,” The Lancet Oncology, vol. 11, no. 2, pp. 184–192, 2010. View at Publisher · View at Google Scholar
  145. C.-S. Chen, J. T. Lin, K. A. Goss, Y.-A. He, J. R. Halpert, and D. J. Waxman, “Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics,” Molecular Pharmacology, vol. 65, no. 5, pp. 1278–1285, 2004. View at Publisher · View at Google Scholar
  146. C. D. Scripture, A. Sparreboom, and W. D. Figg, “Modulation of cytochrome P450 activity: implications for cancer therapy,” The Lancet Oncology, vol. 6, no. 10, pp. 780–789, 2005. View at Publisher · View at Google Scholar
  147. K.-I. Fujita, “Cytochrome P450 and anticancer drugs,” Current Drug Metabolism, vol. 7, no. 1, pp. 23–37, 2006. View at Publisher · View at Google Scholar
  148. M. Furlanut and L. Franceschi, “Phramacology of Ifosfamide,” Oncology, vol. 65, supplement 2, pp. 2–6, 2003. View at Google Scholar
  149. K. Scotlandi, D. Remondini, G. Castellani et al., “Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome,” Journal of Clinical Oncology, vol. 27, no. 13, pp. 2209–2216, 2009. View at Publisher · View at Google Scholar
  150. D. M. Townsend and K.D. Tew, “The role of gluthatione-S-transferasse in anticancer drug resistance,” Oncogene, vol. 22, pp. 7369–7375, 2003. View at Google Scholar
  151. M. Salzer-Kuntschik, G. Delling, G. Beron et al., “Morphologicla grades of regression in osteosarcoma after polychemotherapy COSS 80,” Journal of Cancer Research Clinical Oncology, vol. 106, supplement 1, pp. 21–24, 1983. View at Google Scholar
  152. R. B. Womer, D. C. West, M. D. Krailo et al., “Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family of tumors (ESFT),” Journal of Clinical Oncology, vol. 26, supplement 15, 2008, abstract no. 10504. View at Google Scholar
  153. U. Dirksen and H. Jürgens, “Approaching Ewing sarcoma,” Future Oncology, vol. 6, no. 7, pp. 1155–1162, 2010. View at Publisher · View at Google Scholar
  154. G. Ricci, F. De Maria, G. Antonini et al., “-7,nitro-2,1,3 benzoxadiazole derivatives a new class 0f suicide inhibitors for gluthatione S-transferases . Mechanism of action of potential anticancer drugs,” The Journal of Biological Chemistry, vol. 280, pp. 26397–26405, 2005. View at Google Scholar
  155. E. C. Toomey, J. D. Schiffman, and S. L. Lessnick, “Recent advances in the molecular pathogenesis of Ewing's sarcoma,” Oncogene, vol. 29, no. 32, pp. 4504–4516, 2010. View at Publisher · View at Google Scholar
  156. G. Maire, C. W. Brown, J. Bayani et al., “Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion-insertion mechanism of EWS-ERG fusion gene formation: a case analysis and literature review,” Cancer Genetics and Cytogenetics, vol. 181, no. 2, pp. 81–92, 2008. View at Publisher · View at Google Scholar